ArticleBiotechnology progress
NS0 and CHO cell lines generate distinct quality profiles for non-originator NISTmAbs.
Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NS0 and CHO cell lines generate distinct quality profiles for non-originator NISTmAbs.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The selection of host cell lines and culture media plays a central role in influencing the quality attributes of monoclonal antibodies, particularly in biosimilar development and process comparability. This study used standardized upstream conditions to evaluate the impact of host cell line selection on product quality attributes of a non-originator version of the NISTmAb by comparing results from antibodies made in murine myeloma NS0 or Chinese Hamster Ovary (CHO) cells. NISTCHO and NS0 clones achieved comparable peak density and productivity when cultured identically, demonstrating the critical role of media formulation for NISTCHO performance. Distinct cell line-specific differences were noted in aggregation, fragmentation, charge variant distribution, and glycosylation profiles. Non-originator NISTmAb derived from NS0 cells exhibited glycoforms that were nearly 100% fucosylated with higher relative levels of sialylation and galactosylation. The NS0-derived material also displayed elevated levels of acidic charge variant species, decreased main charge variant species, and increased aggregation. Conversely, non-originator NISTmAb derived from NISTCHO exhibited an average of 15-20% relative afucosylation, resulting in an increased binding affinity to FcγRIIIa, which can be of critical importance to quality due to potential enhancement of ADCC potency. These results highlight the intrinsic biology of the host cell line and culture media composition as influential factors for microheterogeneity in post-translational modifications and structural characteristics. As of December 2025, 14 (17.3%) of FDA-approved biosimilars are manufactured using a different cell type than that of the originator product, necessitating comparisons among cell substrates and their effect on product quality of interest for comparative analytical assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.